Thermo Fisher Scientific Inc. raised about €4.33 billion and $890.68 million in net proceeds from two separate senior notes placements in Europe and the U.S.
In the U.S. offering, that closed Oct. 8, the Waltham, Mass.-based company issued $900 million aggregate principal amount of its 2.6% senior notes due 2029.
Meanwhile, under the the European offering, that closed Sept. 30, the company issued €800 million aggregate principal amount of its 0.125% senior notes due 2025; €800 million aggregate principal amount of its 0.500% senior notes due 2028; €900 million aggregate principal amount of its 0.875% senior notes due 2031; €900 million aggregate principal amount of its 1.5% senior notes due 2039; and €1 billion aggregate principal amount of its 1.875% senior notes due 2049.
The life sciences giant intends to use the proceeds to fund the redemption of the principal amount of several outstanding senior notes, the company said in an Oct. 8 press release.
